Background: Epilepsy is a frequent condition in persons with intellectual disability and is more often difficult to treat than in the average population. Seizure freedom is the primary therapeutic goal which has important implications for the patient's quality of life. The aim of this study was to find out which antiepileptic therapy regimens (monotherapy or combination therapy) are effective in achieving this goal in intellectually disabled epilepsy patients. We were especially interested in the impact of the new antiepileptic drugs (AEDs) which were introduced during the past decade. Method: We investigated retrospectively the antiepileptic regimens on which the resident patients of a large epilepsy centre (as a rule with additional intellectual disabilities of different degrees) were seizure free in 2002. Information on antiepileptic medication and seizure frequency was taken out of the individual case documentation. It was also determined whether seizure free patients had already been seizure free in 1992. Results: Two hundred and forty out of 675 patients (35,6%) with epilepsy were seizure free. The proportion of seizure freedom was 43,7% in patients with borderline intelligence, 39,2% in mild, 33,2% in moderate, 31,9% in severe, and 21,9% in profound intellectual disability. One hundred and twenty-two (50,8%) seizure free patients were on monotherapy; 53 of them were on CBZ (PB: 34, VPA: 25, PHT: 7, LTG: 3). Ninety-three patients (38,7%) were on duotherapies, CBZ/PB (27 patients), PB/PHT (17), and LTG/VPA (14) being the commonest. Of 18 (7,5%) triple therapies, LTG/PB/ VPA (4 patients) was the commonest. Taken together, the five most frequent therapeutic regimens were CBZ monotherapy, PB monotherapy, CBZ/PB, VPA monotherapy and PB/PHT (a clear preponderance of classic AEDs).
Introduction
Epilepsy is a frequent condition in persons with intellectual disability 1 and is more often difficult to treat than in the average population. 2 The main therapeutic goal is complete seizure control; it has major implications for the patient's quality of life and reduces associated morbidity and mortality. 3 Whereas monotherapy is the accepted gold standard in antiepileptic therapy, a number of patients need a combination of (mostly two) drugs. As a consequence of the introduction of more than half a dozen new antiepileptic drugs (AEDs) during the last ten years, the number of possible combinations has increased considerably. An unsolved problem is the paucity of data regarding useful synergistic combinations. It is a common recommendation to combine drugs with different rather than with similar mechanisms of action but this recommendation lacks empirical confirmation.
Stephen and Brodie 4 followed a surprisingly straightforward way to determine effective combinations in their patients: They filtered seizure free patients on combination therapy out of their extensive database and thus found LTG/VPA, 2 PB/PHT, CBZ/GBP, and CBZ/VPA to be the most successful combinations. Although this approach is far from allowing definite conclusions we were fascinated by its pragmatism and decided to undertake a similar investigation in inpatients with epilepsy and intellectual disability. Our aim was to determine therapeutic regimens (monotherapy as well as combination therapy) on which patients were seizure free. We also wanted to find out to what degree the new AEDs have contributed to achieving seizure freedom in intellectually disabled patients.
Materials and methods
The residential department of the Bethel epilepsy centre is a large organisation which provides long term care for patients with epilepsy and different degrees of intellectual and/or physical disabilities (from borderline intelligence to profoundly multihandicapped). A large proportion of the resident population has been living there for decades while others have been admitted more recently. Many of them suffer from difficult-to-treat epilepsies. Our investigation covers nearly the whole institution located near the centre of the city of Bielefeld excluding only two residences which have a different clientele.
Long-term antiepileptic treatment has been carried out by the physicians of the integrated Bethel medical service (mostly neurologists; all with special experience in the diagnosis and treatment of epilepsy). Antiepileptic therapy has always aimed to achieve seizure freedom whenever possible or at least to reach a balance between the best possible seizure control and a minimum of side effects.
Information on the diagnosis of epilepsy (recurrent unprovoked seizures) and epileptic syndrome (based on seizure descriptions and EEG findings, according to the International League Against Epilepsy ILAE classification) 5 was taken from the individual case histories. Information on antiepileptic medication in 2002 was extracted from the current case documentation. Seizure charts have been kept for decades for every resident patient in order to record all seizures observed in the residential homes and also in the workshops or day centres; they were used for information on seizure frequency. Patients were denoted as completely seizure free (no seizure at all in 2002) or nearly seizure free (compatible with one uncomplicated seizure during the whole year; or with one or two seizures because of acute disease or forgotten medication; or with isolated auras). Medication was mostly stable throughout the whole year 2002; if not, certain rules were applied to choose the key date (longest period of time with 382 B. Huber et al.
A distinction was made between ''old seizure free'' (seizure free already in 1992) and ''new seizure free'' (in 1992 still seizures) patients. In the 132 old seizure free patients the classic AEDs prevailed again, monotherapies with CBZ, PB and VPA being the most frequent regimens. In comparison, in the 78 new seizure free 1 patients the novel combination LTG/VPA was the third most frequent, after the classic regimens CBZ/PB and CBZ; PB monotherapies were rare. Conclusion: In a majority of intellectually disabled patients with epilepsy (including those who became seizure free since 1992), complete seizure control has been achieved by monotherapy or duotherapy with classic AEDs. Of the new AEDs LTG in combination with VPA appears to be an important innovation. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved. stable medication; day when a [trough] serum level was determined; if more than one trough serum levels: the latest).
As the organisation is specialising in epilepsy and great efforts have been made for correct seizure documentation in all resident patients it can be assumed the seizure documentation was as accurate as possible.
In those patients who were admitted to the institution before 1992, seizure frequency in 1992 was evaluated in the same way.
Results
Out of 867 residents, 677 had a diagnosis of epilepsy; 2 of these had to be excluded because frequent additional psychogenic non-epileptic attacks rendered the evaluation impossible. Of the remaining 675, 240 patients or 35,4% were seizure free in 2002 (182 patients completely seizure free, 58 nearly seizure free; 122 male, 118 female; all adults except two adolescents). 122 (50,8%) of the seizure free were on monotherapy, 114 (47,5%) were on combinations of two or more AEDs ( Table 1 ).
The monotherapies
Seizure free patients were on five different AEDs in monotherapy, mainly the ''classic'' drugs (Fig. 1) .
The duotherapies
CBZ/PB was the most frequent duotherapy followed by PB/PHT and LTG/VPA (Fig. 2) .
The triple therapies
Within the small number of successful triple therapies, only the combination LTG/PB/VPA occurred more than twice (Fig. 3) .
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The different therapeutic regimens in different degrees of intellectual disability
The proportion of seizure free patients was 38 of 87 patients (43,7%) with borderline intelligence/learning difficulty, 3 71 of 181 patients (39,2%) with mild, 75 of 226 patients (33,2%) with moderate, 46 of 144 patients (31,9%) with severe, and 7 of 32 patients (21,9%) with profound intellectual disability. The therapeutic regimens on which patients with different degrees of intellectual disability were seizure free are shown in Fig. 6 .
The different therapeutic regimens in the different epilepsy syndromes
The rates of seizure freedom were lowest in Lennox-Gastaut syndrome (4% of 50 patients) and in multifocal epilepsies (11,5% of 52 patients) both known to be difficult to treat types of epilepsy, and highest in idiopathic generalised epilepsy (58,3% of 24 patients), a relatively benign epileptic syndrome which is less common in intellectually disabled patients. The other proportions were 38,0% of 308 patients with symptomatic or cryptogenic focal epilepsy, 30,0% of 143 patients with epilepsy with focal and generalised seizures, 4 and 62,3% of 69 patients with symptomatic or cryptogenic generalised epilepsy. Fig. 7 gives the therapeutic regimens on which patients with the different syndromes were seizure free. The uneven syndrome distribution and the small case numbers in the less frequent syndromes make it difficult to draw conclusions as for the efficacy of certain combinations in different syndromes.
Discussion
We are aware that a retrospective study like this has its limitations. Results obtained in a special population cannot be generalised about an average epi-384 B. Huber et al. lepsy population. Furthermore, the results do not reflect exclusively the efficacy of different therapy regimens, but also different therapy strategies or prescribing habits. However, prescribing habits emerge out of the physicians cumulating experiences with their individual patients thus reflecting the efficacy of different therapeutic approaches. The views and wishes of family members or legal representatives are among other factors which may have exerted influence on AED treatment. Main strengths may be the large case number and first of all the excellent quality of data which was guaranteed by the high proportion of trained staff and the accuracy of long term seizure documentation which is carried out in all inpatients.
The proportion of seizure freedom was much lower than the rates of approx. three quarter usually reported in the literature and still lower than the 56% in the Stephen and Brodie 4 study. This reflects the high rate of therapy resistance in intellectually disabled epilepsy patients and also the selected clientele of an epilepsy centre. The same is for the rate of monotherapy which was lower than one might expect. The figure of 78 new seizure free patients in such a difficult-to-treat clientele points out that continuing efforts to optimise antiepileptic therapy are worthwhile.
A main message of the study may be not to forget the classic AEDs. After a decade during which therapy studies tended to focus on the new AEDs, and our own efforts to improve the seizure situation of the resident patients were also mainly based on the new AEDs, we were surprised to find out that still the great majority of seizure free patients were on classic AEDs. We first assumed this finding might be due to the high proportion of long term seizure free patients. However, even more surprisingly, even in the patients who became seizure free after 1992 classic therapeutic regimens such as CBZ/PB and CBZ monotherapy prevailed (Fig. 5) . On the other hand, the combination LTG/VPA which is the third frequent in the new seizure free is a major innovation.
During the past years we have treated many of the therapy-resistant resident patients with some of the new AEDs. We have seen a 50% seizure reduction in 28,8% on LTG, 6 in 37,5% on TPM, 7 and in 41,3% on LEV. 8 The number of seizure free patients however was extremely low in these studies, a fact which is in concordance with the results presented here.
The usefulness of the combination LTG/VPA in intellectually disabled patients has been stressed by other workers too. 4, 9 The minor role of new AEDs, apart from LTG, may be due to diverse reasons. In our experience the efficacy of GBP is low in the difficult-to-treat epilepsy of intellectually disabled patients. 10 TPM appears to be more toxic in disabled patients than otherwise reported. 7 LEV has been marketed only recently (autumn 2000 in Germany) and its broader use may be a question of time. It is much more difficult to explain why OCBZ is nearly not found in successful therapy regimens. One possible reason might be that OCBZ which has metabolic advantages over CBZ was more often administered (e.g. replacing CBZ) with the aim of better tolerability rather than optimising seizure frequency.
Although there is no doubt that there has been some progress for the intellectually disabled epilepsy patient through the new AEDs, seizure freedom, the main therapeutic goal, has been accomplished for the main part by the classic AEDs in a sample of patients with chronic epilepsies and intellectual disability residing in a large epilepsy centre. Even in the patients who have become seizure free since 1992 (within the decade of the new AEDs) more patients have benefited from traditional rather from new AEDs. The only exception was the combination LTG/VPA which appears to be an important innovation.
Despite the expansion of therapeutic options during the last decade, two thirds of the resident patients of an epilepsy centre are not seizure free, further innovation is urgently needed. Figure 7 The different therapeutic regimens in the different epilepsy syndromes. sy/crypt foc epi: symptomatic or cryptogenic focal epilepsy; sy/crypt gen epi: symptomatic or cryptogenic generalised epilepsy; foc + -gen epi: epilepsies with both generalised and focal seizures; idiopathic gen epi: idiopathic generalised epilepsy.
